Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1042 first-in-human trial in advanced malignant solid tumors
2023-508526-10-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Oct 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of tecaginlimab in Non-hematologic malignancy, melanoma, non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicity and Objective response rate. Started Oct 2019; status: completed.
02
Drugs
tecaginlimab
03
Conditions
Non-hematologic malignancymelanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-508526-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508526-10-00.